<DOC>
	<DOCNO>NCT02205398</DOCNO>
	<brief_summary>This open-label , phase Ib , multicenter clinical trial determine MTD/RDE orally administer c-MET inhibitor INC280 combination cetuximab . This combination explore c-MET positive mCRC HNSCC patient whose disease progress cetuximab panitumumab treatment . The dose escalation part guide Bayesian Logistic Regression Model overdose control . At MTD/RDE , additional mCRC HNSCC patient progress cetuximab panitumumab treatment enrol two expansion group assess anti-tumor activity safety tolerability combination INC280 cetuximab . Patients receive INC280 continuous bid dose regimen cetuximab every week . A treatment cycle define 28 day schedule break cycle .</brief_summary>
	<brief_title>Study Safety Efficacy INC280 Cetuximab , Adult c-MET Positive mCRC HNSCC Patients After Progression Cetuximab Panitumumab Therapy</brief_title>
	<detailed_description />
	<mesh_term>Carcinoma , Squamous Cell</mesh_term>
	<mesh_term>Colorectal Neoplasms</mesh_term>
	<mesh_term>Head Neck Neoplasms</mesh_term>
	<mesh_term>Cetuximab</mesh_term>
	<criteria>Male female age ≥ 18 year Metastatic colorectal cancer head neck squamous cell carcinoma cMET positive ( defined cMET IHC intensity score +2 ≥ 50 % tumor cell MET gene copy number ≥ 5 FISH IHC intensity score +3 ≥ 50 % tumor cell ) K/NRAS WT status mCRC patient At least one previous line treatment metastatic disease last treatment must include cetuximab panitumumab . Documentation clinical benefit subsequent progression cetuximab panitumumab recent line treatment required patient expansion part Measurable disease per RECIST v1.1 ECOG performance status ≤ 2 Prior treatment cMET/HGF inhibitor History severe reaction cetuximab and/or panitumumab ( except G3 rash G3 hypomagnesaemia ) History acute chronic pancreatitis Active bleeding within 4 week prior screen visit Symptomatic brain metastasis Feeding tube dependence Not adequate hematologic , renal hepatic function Other protocoldefined inclusion/exclusion criterion may apply NVS Definition : List main study specific inclusion/exclusion criterion patient understand . Note : DO NOT cut/paste directly protocol . Do include age gender part field . Age gender indicate 2 field . Always include statement `` Other protocoldefined inclusion/exclusion criterion may apply '' end section . Examples : Inclusion criterion : Patients within 7 42 day acute myocardial infarction associate leave ventricular systolic dysfunction Qualifying Echocardiogram Visit 1 Exclusion criterion : Presence clinically overt heart failure Percutaneous coronary intervention ( PCI ) less 24 hour randomization previous treatment aliskiren Other protocoldefined inclusion/exclusion criterion may apply .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>March 2017</verification_date>
	<keyword>INC280</keyword>
	<keyword>c-MET inhibitor</keyword>
	<keyword>cetuximab</keyword>
	<keyword>metastatic colorectal cancer</keyword>
	<keyword>head neck</keyword>
	<keyword>squamous cell carcinoma</keyword>
	<keyword>resistance cetuximab/panitumumab</keyword>
</DOC>